vivace 2.5mg tableta
"evropa lek pharma" doo podgorica - ramipril - tableta - 2.5mg
rivarox 15mg film tableta
"glk pharma" druŠtvo sa ograniČenom odgovornoŠĆu, podgorica - rivaroksaban - film tableta - 15mg
rivarox 10mg film tableta
"glk pharma" druŠtvo sa ograniČenom odgovornoŠĆu, podgorica - rivaroksaban - film tableta - 10mg
rivarox 20mg film tableta
"glk pharma" druŠtvo sa ograniČenom odgovornoŠĆu, podgorica - rivaroksaban - film tableta - 20mg
bonviva 150mg film tableta
"evropa lek pharma" doo podgorica - ibandronska kiselina - film tableta - 150mg
stivarga 40mg film tableta
"evropa lek pharma" doo podgorica - regorafenib - film tableta - 40mg
bonviva 3mg/3ml rastvor za injekciju
"evropa lek pharma" doo podgorica - ibandronska kiselina - rastvor za injekciju - 3mg/3ml
vivace 1.25mg tableta
"evropa lek pharma" doo podgorica - ramipril - tableta - 1.25mg
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti za dermatitis, isključujući kortikosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
nulibry
tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - drugi gastrointestinalni trakt i metabolizam, lijekovi, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.